摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[[4,6-Dimethyl-2-(phenethylamino)benzimidazol-1-yl]methyl]-6-methyl-pyridin-3-ol

中文名称
——
中文别名
——
英文名称
2-[[4,6-Dimethyl-2-(phenethylamino)benzimidazol-1-yl]methyl]-6-methyl-pyridin-3-ol
英文别名
2-[[4,6-dimethyl-2-(2-phenylethylamino)benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
2-[[4,6-Dimethyl-2-(phenethylamino)benzimidazol-1-yl]methyl]-6-methyl-pyridin-3-ol化学式
CAS
——
化学式
C24H26N4O
mdl
——
分子量
386.497
InChiKey
HLGWGMNUXMHXFV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    63
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    4,6-dimethyl-N-(2-phenylethyl)-1H-benzimidazol-2-amine 、 2-(氯甲基)-6-甲基吡啶-3-醇盐酸盐potassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 12.0h, 以0.06 g的产率得到2-[[4,6-Dimethyl-2-(phenethylamino)benzimidazol-1-yl]methyl]-6-methyl-pyridin-3-ol
    参考文献:
    名称:
    Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate, Part 1:  Improving the Pharmacokinetic Profile Using the Structure−Property Relationship
    摘要:
    We previously reported the discovery of substituted benzimidazole fusion inhibitors with nanomolar activity against respiratory syncytial virus (Andries, K.; et al. Antiviral Res. 2003, 60, 209-219). A lead compound of the series was selected for preclinical evaluation. This drug candidate, JNJ-2408068 (formerly R 17059 1, 1), showed long tissue retention times in several species (rat, dog, and monkey), creating cause for concern. We herein describe the optimization program to develop compounds with improved properties in terms of tissue retention. We have identified the aminoethyl-piperidine moiety as being responsible for the long tissue retention time of 1. We have investigated the replacement or the modification of this group, and we suggest that the pK(a) of this part of the molecules influences both the antiviral activity and the pharmacokinetic profile. We were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue.
    DOI:
    10.1021/jm070143x
点击查看最新优质反应信息